


Eurofins Discovery, PharmaResources announce commercial cooperation

05 February 2020 | News

To provide PharmaResources' customers with expedited access to Eurofins Discovery's pharmacology and ADMET portfolio



Eurofins Discovery, the leading provider of services and products to the drug discovery industry, and PharmaResources, a leading Contract Research Organization (CRO) based in Shanghai, China, specializing in small molecule drug R&D and manufacture, announced a commercial cooperation to provide PharmaResources' customers with expedited access to Eurofins Discovery's pharmacology and ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) portfolio to accelerate their client's drug discovery timelines.

PharmaResources' 300 chemists and 30+ drug discovery programs will be able to provide their customers with *in vitro* pharmacology and ADME assessments, which enables earlier and faster access to safety and efficacy data through a single integrated platform.

The cooperation improves R&D efficiency as medicinal chemists at PharmaResources will have rapid access to pharmacology and ADMET data through this cooperation with Eurofins Discovery.

"Our commitment to reducing the time and cost of drug discovery to worldwide pharmaceutical clients, and especially those in China, is enriched through Eurofins Discovery's biology platforms with the discovery chemistry platform of PharmaResources," said Christina Shasserre, SVP of Eurofins Discovery. "PharmaResources is an internationally recognized leader in medicinal and process chemistry with outstanding track records in early drug discovery and shares our vision of reducing the time it takes to generate safe and efficacious therapies for drug developers."